Sublingual immunotherapy: focus on tablets

Annals of Allergy, Asthma & Immunology

July 2015 Volume 115, Issue 1, Pages 4-9  MOC-CME Review


Overall Purpose
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.


Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Planning Committee Members
Giovanni Passalacqua, MD (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)            

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Recognize the clinical value of tablets for sublingual immunotherapy (SLIT)
Identify indications and contraindications for SLIT with tablets currently approved in the U.S

Additional information
Disclosure: 

N. Salzman has received research grants from the National Institutes of Health (NIH) and the Crohn’s and Colitis Foundation of America. M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, and National Institutes of Health (NIH). Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.   

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
07/01/2015
Course expires: 
06/30/2017
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC

Accreditation Period

Course opens: 
07/01/2015
Course expires: 
06/30/2017

Price

Cost:
$0.00
Please login or create an account to take this course.